Robert Davis, Merck CEO
November 4, 2021 07:28 AM EDTUpdated 10:00 AM
Coronavirus

Covid-19 roundup: Mod­er­na's stock plunges af­ter low­er sales fore­cast is re­vealed; Re­gen­eron sees $804M in Q3 mon­o­clon­al an­ti­body sales

Nicole DeFeudis

Editor

Mod­er­na’s stock $MR­NA plunged more than 14% in pre­mar­ket trad­ing on Thurs­day af­ter the biotech cut its end-of-year vac­cine sales fore­cast.

Ac­cord­ing to its Q3 …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

Out­look's shares crash as wet AMD drug flunks Phase 3 test

A service from the Financial Times